Volcano to provide IVUS imaging for AstraZeneca SATURN statin trial
AstraZeneca-sponsored SATURN clinical trial will use the Volcano Revolution 45 MHz intravascular ultrasound (IVUS) imaging catheter from Volcano, as part of its imaging protocol.
SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) is a 104-week, parallel-group, multicenter, double-blind, Phase IIIb IVUS imaging study of approximately 1,300 patients at 170 centers worldwide.
The AstraZeneca trial will measure the impact of 40-mg rosuvastatin (Astra’s Crestor) and 80-mg atorvastatin (Pfizer’s Lipitor) on the progression of atherosclerosis in high-risk patients, following two years of treatment in patients with coronary artery disease, according to San Diego-based Volcano.
Steve Nissen, MD, along with Steve Nichols, MD, principal investigator from the Cleveland Clinic Core Lab, chairs the SATURN trial.
SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) is a 104-week, parallel-group, multicenter, double-blind, Phase IIIb IVUS imaging study of approximately 1,300 patients at 170 centers worldwide.
The AstraZeneca trial will measure the impact of 40-mg rosuvastatin (Astra’s Crestor) and 80-mg atorvastatin (Pfizer’s Lipitor) on the progression of atherosclerosis in high-risk patients, following two years of treatment in patients with coronary artery disease, according to San Diego-based Volcano.
Steve Nissen, MD, along with Steve Nichols, MD, principal investigator from the Cleveland Clinic Core Lab, chairs the SATURN trial.